INS and Hypoglycemia: Our study concept is also similar to recently published studies, except that they used iGlaLixi fixed combination therapy.[25,26] Similar to our results, body weight, HbA1c, and therapeutic total insulin dose can be adjusted by changing the therapeutic strategy improved by GLP-1RA plus basal insulin; and also did not increase the risk of hypoglycemia.